Winicker-Norimed GmbH Medizinische Forschung
Winicker-Norimed GmbH Medizinische Forschung is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
OPUS-2 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy
Sponsor Viatris Innovation GmbH
- Start (EU)
- Latest update
- Estimated end
A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)
Sponsor Immatics US Inc.
- Start (EU)
- Latest update
- Estimated end
A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors
Sponsor Immatics US Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Prospective, open-label, multicenter, initially 1-arm and, in the event of treatment failure, 3-arm randomised phase III/IV clinical trial on escalating treatment of scabies with INFECTOSCAB 5% (permethrin) (stage I) - with consecutive investigation of the efficacy and safety of two escalated treatment regimens for the treatment of scabies with a higher-concentration permethrin cream (stage II).
Sponsor INFECTOPHARM Arzneimittel und Consilium GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Prospective, multistage, two-arm, randomised, double-blind study on the efficacy and safety of treatment of mild to moderate actinic keratosis with a 5% potassium hydroxide solution versus placebo with different duration of treatment cycles
Sponsor INFECTOPHARM Arzneimittel und Consilium GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, parallel-group, double-blind, placebo-controlled, multicenter trial to investigate the efficacy and safety of subcutaneously administered secukinumab in patients with new-onset of giant cell arteritis (GCA) who are in clinical remission and eligible for treatment with glucocorticoidmonotherapy (GigAINt)
Sponsor Novartis Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, double-blind, placebo-controlled dose-finding study of 0.05%, 0.025%, 0.01% and 0.005% atropine eye drops to inhibit myopia progression in children in a European population
Sponsor Pharma Stulln GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Winicker-Norimed GmbH Medizinische Forschung?
The 2026-10-09 snapshot links Winicker-Norimed GmbH Medizinische Forschung to 7 distinct CTIS trials. Recorded services include Data management, Medical writing, Statistical analysis, Clinical monitoring, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Winicker-Norimed GmbH Medizinische Forschung?
The most frequently recorded therapeutic areas are Immunology, Rheumatology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Winicker-Norimed GmbH Medizinische Forschung conducted?
The linked trials record locations in 7 countries, including Germany, Czechia, Spain, France, Netherlands. These are trial locations, not confirmed office locations or countries where Winicker-Norimed GmbH Medizinische Forschung delivered services.
What can this page tell me about Winicker-Norimed GmbH Medizinische Forschung's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Winicker-Norimed GmbH Medizinische Forschung. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Winicker-Norimed GmbH Medizinische Forschung